Zhang, Chen-Song http://orcid.org/0000-0001-5218-0101
Li, Mengqi http://orcid.org/0000-0002-1171-5648
Wang, Yu
Li, Xiaoyang
Zong, Yue
Long, Shating
Zhang, Mingliang
Feng, Jin-Wei
Wei, Xiaoyan
Liu, Yan-Hui
Zhang, Baoding
Wu, Jianfeng
Zhang, Cixiong
Lian, Wenhua
Ma, Teng
Tian, Xiao
Qu, Qi
Yu, Yaxin
Xiong, Jinye
Liu, Dong-Tai http://orcid.org/0000-0002-7293-9717
Wu, Zhenhua
Zhu, Mingxia http://orcid.org/0000-0002-1858-5655
Xie, Changchuan http://orcid.org/0000-0002-1078-0464
Wu, Yaying
Xu, Zheni http://orcid.org/0000-0001-7926-0259
Yang, Chunyan
Chen, Junjie
Huang, Guohong
He, Qingxia http://orcid.org/0000-0001-8340-7305
Huang, Xi
Zhang, Lei
Sun, Xiufeng
Liu, Qingfeng
Ghafoor, Abdul
Gui, Fu http://orcid.org/0000-0001-8329-7118
Zheng, Kaili
Wang, Wen http://orcid.org/0000-0003-0986-8853
Wang, Zhi-Chao
Yu, Yong
Zhao, Qingliang
Lin, Shu-Yong http://orcid.org/0000-0002-4419-1713
Wang, Zhi-Xin
Piao, Hai-Long http://orcid.org/0000-0001-7451-0386
Deng, Xianming http://orcid.org/0000-0002-9354-5864
Lin, Sheng-Cai http://orcid.org/0000-0003-1993-8376
Funding for this research was provided by:
Ministry of Education of the People’s Republic of China (#BP2018017)
Xiamen University (#20720200069, 2020Y1021, #20720190084)
National Natural Science Foundation of China (#82088102, #91854208, #92157001, #31922034, #92057204, #32070753, #22025702, #82021003, #82151211, #91853203)
Ministry of Science and Technology of the People’s Republic of China (2020YFA0803402, 2017YFA0504504)
Article History
Received: 2 March 2022
Accepted: 16 August 2022
First Online: 10 October 2022
Competing interests
: The compounds described in this paper have been filed for a patent application (WO 2018184561). Authors X.D., C.-S.Z. and S.-C.L. are listed as inventors on the patent (WO 2018184561) on the therapeutic use of aldometanib and other aldometanib derivatives. All other authors declare no competing interests.